INTRODUCTION: This open-label, phase I/II study assessed safety and efficacy of rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting delta-like protein 3 plus immune checkpoint inhibitors nivolumab ± ipilimumab in previously treated extensive-stage small cell lung cancer (ES SCLC).METHODS: Patients with histologically/cytologically confirmed, previously treated (two or more lines of therapy) ES SCLC were enrolled into two cohorts. Cohort 1 received 0.3 mg/kg Rova-T (once every 6 weeks for two cycles) plus 360 mg nivolumab (two 3-week cycles beginning on week 4). Cohort 2 received the same dosage of Rova-T as Cohort 1 plus 1 mg/kg nivolumab (four 3-week cycles) and 1 mg/kg ipilimumab (beginning week 4). Both cohorts received 480 mg nivolumab every 4 weeks starting at week 10.Key objectives were to assess safety/tolerability and efficacy (per RECIST v1.1). The response-related results are based on centrally read data.RESULTS: Forty-two patients received therapy: cohort 1, n=30; cohort 2, n=12. Overall, 43% received two or more prior lines of therapy. All patients experienced one or more treatment-emergent adverse event (TEAE); 41 patients reported AEs considered related to study drug by the investigator. The most frequent TEAE was pleural effusion (n=20, 48%); most common grade ≥3 was anemia (n=9, 21%). Three grade 5 TEAEs considered related to study drug were reported (cohort 1): pneumonitis (n=2), acute kidney injury (n=1). The objective response rate was 30% (12/40): cohort 1, 27.6% (8/29); cohort 2, 36.4% (4/11); all partial responses.CONCLUSIONS: Despite encouraging antitumor activity in previously treated ES SCLC, combination therapy with Rova-T and nivolumab ± ipilimumab was not well tolerated at the dose levels and administration schedules evaluated.

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer / J. Malhotra, P. Nikolinakos, T. Leal, J. Lehman, D. Morgensztern, J.D. Patel, J.M. Wrangle, G. Curigliano, L. Greillier, M.L. Johnson, N. Ready, G. Robinet, S. Lally, D. Maag, R. Valenzuela, V. Blot, B. Besse. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - (2021). [Epub ahead of print]

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer

G. Curigliano
Conceptualization
;
2021

Abstract

INTRODUCTION: This open-label, phase I/II study assessed safety and efficacy of rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting delta-like protein 3 plus immune checkpoint inhibitors nivolumab ± ipilimumab in previously treated extensive-stage small cell lung cancer (ES SCLC).METHODS: Patients with histologically/cytologically confirmed, previously treated (two or more lines of therapy) ES SCLC were enrolled into two cohorts. Cohort 1 received 0.3 mg/kg Rova-T (once every 6 weeks for two cycles) plus 360 mg nivolumab (two 3-week cycles beginning on week 4). Cohort 2 received the same dosage of Rova-T as Cohort 1 plus 1 mg/kg nivolumab (four 3-week cycles) and 1 mg/kg ipilimumab (beginning week 4). Both cohorts received 480 mg nivolumab every 4 weeks starting at week 10.Key objectives were to assess safety/tolerability and efficacy (per RECIST v1.1). The response-related results are based on centrally read data.RESULTS: Forty-two patients received therapy: cohort 1, n=30; cohort 2, n=12. Overall, 43% received two or more prior lines of therapy. All patients experienced one or more treatment-emergent adverse event (TEAE); 41 patients reported AEs considered related to study drug by the investigator. The most frequent TEAE was pleural effusion (n=20, 48%); most common grade ≥3 was anemia (n=9, 21%). Three grade 5 TEAEs considered related to study drug were reported (cohort 1): pneumonitis (n=2), acute kidney injury (n=1). The objective response rate was 30% (12/40): cohort 1, 27.6% (8/29); cohort 2, 36.4% (4/11); all partial responses.CONCLUSIONS: Despite encouraging antitumor activity in previously treated ES SCLC, combination therapy with Rova-T and nivolumab ± ipilimumab was not well tolerated at the dose levels and administration schedules evaluated.
Lung cancer; antibody-drug conjugates; clinical trials; immunotherapy; small-molecule agents;
Settore MED/06 - Oncologia Medica
27-feb-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Rovalpituzumab Curigliano 2021.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 574.86 kB
Formato Adobe PDF
574.86 kB Adobe PDF Visualizza/Apri
1-s2.0-S1556086421017457-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 384.31 kB
Formato Adobe PDF
384.31 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/825223
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 17
social impact